Catheter Precision Reports Surge in LockeT Device Hospital Approvals and Strong Q1 Adoption Outlook

Reuters

Feb 04

Catheter Precision Reports Surge in LockeT Device Hospital Approvals and Strong Q1 Adoption Outlook

Catheter Precision Inc. (NYSE American: VTAK) reported increased hospital evaluations and approvals for its LockeT suture retention device as it entered the first quarter of 2026. The company recorded its highest revenue for the month of January and expanded into several international markets. Catheter Precision has also secured approvals for LockeT evaluations at additional high-volume centers in the United States, including institutions such as Johns Hopkins, University of Michigan, Beth Israel in Boston, Northside hospitals in Atlanta, and Scripps in Southern California. The company attributes adoption momentum to LockeT's operational efficiency, rapid staff onboarding, and cost-effectiveness, including support for same-day discharge and reduced bed rest. Catheter Precision continues to expand in the European market following CE Mark approval, aiming for further adoption throughout the first quarter of 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Catheter Precision Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9648498-en) on February 04, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Trading app for stocks, options & ETFs","description":"Invest in US, ASX, HK, China A-shares, ETFs & options with Tiger Brokers, Australia's trusted stock trading app!","keywords":"tiger brokers,tiger brokers au,tiger brokers australia,tiger trade,tiger trading,australia stock platform,US option,US stocks,stocks and options,australian trading platform,online broker australia,stock trading apps,mobile trading app,desktop trading,chess sponsored brokers,share trading platform","social":{"ogDescription":"Invest in US, ASX, HK, China A-shares, ETFs & options with Tiger Brokers, Australia's trusted stock trading app!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2608648173"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"AUS","license":"TBAU","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2608648173\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2608648173?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-04 21:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2608648173","market":"us","top_or_hot":-1,"title":"Catheter Precision Reports Surge in LockeT Device Hospital Approvals and Strong Q1 Adoption Outlook","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Catheter Precision Reports Surge in LockeT Device Hospital Approvals and Strong Q1 Adoption Outlook\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/VTAK\">Catheter Precision Inc.</a> (NYSE American: VTAK) reported increased hospital evaluations and approvals for its LockeT suture retention device as it entered the first quarter of 2026. The company recorded its highest revenue for the month of January and expanded into several international markets. Catheter Precision has also secured approvals for LockeT evaluations at additional high-volume centers in the United States, including institutions such as Johns Hopkins, University of Michigan, Beth Israel in Boston, Northside hospitals in Atlanta, and Scripps in Southern California. The company attributes adoption momentum to LockeT's operational efficiency, rapid staff onboarding, and cost-effectiveness, including support for same-day discharge and reduced bed rest. Catheter Precision continues to expand in the European market following CE Mark approval, aiming for further adoption throughout the first quarter of 2026.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Catheter Precision Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9648498-en) on February 04, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Catheter Precision Reports Surge in LockeT Device Hospital Approvals and Strong Q1 Adoption Outlook</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCatheter Precision Reports Surge in LockeT Device Hospital Approvals and Strong Q1 Adoption Outlook\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-02-04 21:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Catheter Precision Reports Surge in LockeT Device Hospital Approvals and Strong Q1 Adoption Outlook\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/VTAK\">Catheter Precision Inc.</a> (NYSE American: VTAK) reported increased hospital evaluations and approvals for its LockeT suture retention device as it entered the first quarter of 2026. The company recorded its highest revenue for the month of January and expanded into several international markets. Catheter Precision has also secured approvals for LockeT evaluations at additional high-volume centers in the United States, including institutions such as Johns Hopkins, University of Michigan, Beth Israel in Boston, Northside hospitals in Atlanta, and Scripps in Southern California. The company attributes adoption momentum to LockeT's operational efficiency, rapid staff onboarding, and cost-effectiveness, including support for same-day discharge and reduced bed rest. Catheter Precision continues to expand in the European market following CE Mark approval, aiming for further adoption throughout the first quarter of 2026.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Catheter Precision Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9648498-en) on February 04, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4082","symbol_name":"医疗保健设备","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260204:nNDL8D6pT:1","article_id":"2608648173","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2608648173","pubTimestamp":1770210051,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Catheter Precision Inc.  reported increased hospital evaluations and approvals for its LockeT suture retention device as it entered the first quarter of 2026. The company recorded its highest revenue for the month of January and expanded into several international markets. Catheter Precision has also secured approvals for LockeT evaluations at additional high-volume centers in the United States, including institutions such as Johns Hopkins, University of Michigan, Beth Israel in Boston, Northside hospitals in Atlanta, and Scripps in Southern California. The company attributes adoption momentum to LockeT's operational efficiency, rapid staff onboarding, and cost-effectiveness, including support for same-day discharge and reduced bed rest. Catheter Precision continues to expand in the European market following CE Mark approval, aiming for further adoption throughout the first quarter of 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intel","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4082":"医疗保健设备","SG9999014005.SGD":"United Global Durable Equities Fund Acc SGD","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","SG9999014013.SGD":"United Global Durable Equities Fund Dis SGD","SG9999014021.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) ACC","NDAQ":"纳斯达克OMX交易所","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","VTAK":"Catheter Precision Inc.","SG9999014039.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) INC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","BK4588":"碎股","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","BK4112":"金融交易所和数据","BK4585":"ETF&股票定投概念","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD"},"translate_title":"Catheter Precision报告LockeT设备医院批准量激增，第一季度采用前景强劲","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NDAQ":0.9,"VTAK":0.9},"content_text":"Catheter Precision Reports Surge in LockeT Device Hospital Approvals and Strong Q1 Adoption Outlook\n    \n\nCatheter Precision Inc. (NYSE American: VTAK) reported increased hospital evaluations and approvals for its LockeT suture retention device as it entered the first quarter of 2026. The company recorded its highest revenue for the month of January and expanded into several international markets. Catheter Precision has also secured approvals for LockeT evaluations at additional high-volume centers in the United States, including institutions such as Johns Hopkins, University of Michigan, Beth Israel in Boston, Northside hospitals in Atlanta, and Scripps in Southern California. The company attributes adoption momentum to LockeT's operational efficiency, rapid staff onboarding, and cost-effectiveness, including support for same-day discharge and reduced bed rest. Catheter Precision continues to expand in the European market following CE Mark approval, aiming for further adoption throughout the first quarter of 2026.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Catheter Precision Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9648498-en) on February 04, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}